Trials / Completed
CompletedNCT01023685
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAD106 |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2009-12-02
- Last updated
- 2020-12-17
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01023685. Inclusion in this directory is not an endorsement.